Applying community-based participatory research principles and approaches in clinical trials: forging a new model for cancer clinical research.
Applying community-based participatory research principles and approaches in clinical trials: forging a new model for cancer clinical research.
复制标题
DOI：
10.1353/cpr.0.0103
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Collins, Stacy
中科院分区：
文献类型：
--
作者：
Seifer, Sarena D;Michaels, Margo;Collins, Stacy
尽管估计有20%的成年癌症患者在医学上有资格参加癌症治疗临床试验（CCT），但美国的成人试验参与率仍低于3%。参与率在少数民族和种族以及医疗服务不足的人群中甚至更低，他们的癌症死亡率往往高于整个人口。鉴于这些人群中持续存在的癌症健康差异，参与癌症临床试验越来越成为社会正义的问题。基于社区的参与性研究（CBPR）方法已被多次推荐为增加和多样化癌症临床试验参与并提高其相关性和质量的关键策略。2006年，社区-校园健康伙伴关系（CCPH）和推进癌症临床试验教育网络（ENACCT）获得了医疗保健研究和质量机构和国家癌症研究所（NCI）的资助，沿着行业和非营利合作伙伴，制定了第一套在多地点，III期癌症临床试验中采用CBPR方法的国家建议。社区作为癌症临床试验的合作伙伴：通过一个国家咨询委员会、两次利益攸关方会议和一个公共审查程序编写的《不断变化的研究、实践和政策》最后报告，该报告提出了50多项详细建议，以具体和有意义的方式在整个癌症临床试验过程中吸引社区参与。1该报告首次提供了关于临床试验如何以及为什么应该让受癌症影响的社区参与--从试验设计到实施再到结果传播。本文介绍了该倡议的背景和理由，用于开发和传播该报告的过程，以及实施该报告的基于社区的癌症临床研究方法的挑战和机遇。
Although an estimated 20% of adult cancer patients are medically eligible for a cancer treatment clinical trial (CCT), adult trial participation in the U.S. remains under 3%.- Participation rates are even lower among ethnic and racial minorities and the medically underserved, who tend to have higher cancer mortality rates than the population as a whole.- Given persistent cancer health disparities in these populations, cancer clinical trial participation is increasingly an issue of social justice. Community-based participatory research (CBPR) approaches have been repeatedly recommended as a key strategy for increasing and diversifying cancer clinical trial participation and enhancing their relevance and quality. In 2006, Community-Campus Partnership for Health (CCPH) and the Education Network to Advance Cancer Clinical Trials (ENACCT) received funding from the Agency for Healthcare Research and Quality and the National Cancer Institute (NCI), along with industry and nonprofit partners, to develop the first set of national recommendations to employ CBPR approaches in multisite, phase III cancer clinical trials. The Communities as Partners in Cancer Clinical Trials: Changing Research, Practice and Policy final report, developed through a national advisory committee, two stakeholder meetings and a public vetting process, makes more than fifty detailed recommendations to engage communities in specific and meaningful ways throughout the cancer clinical trial process.1 The report is the first to provide specific guidance as to how and why clinical trials should involve communities affected by cancer-from trial design to implementation to dissemination of results. This paper describes the background and rationale for the initiative, the process used to develop and disseminate the report, and the challenges and opportunities for implementing the report's community-based approaches to cancer clinical research.